[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.41.181. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 1977

Calmette-Guerin Bacillus Treatment of Experimental Conjunctival Malignant Melanoma

Author Affiliations

From the Department of Ophthalmology, University of Illinois Eye and Ear Infirmary, Chicago.

Arch Ophthalmol. 1977;95(12):2214-2217. doi:10.1001/archopht.1977.04450120120017
Abstract

• Malignant melanoma of the conjunctival region was induced in the golden Syrian hamster. Inoculation of this lesion with Calmette-Guerin bacillus (BCG), 48 hours after injection of 103 tumor cells, either slowed, limited, or completely prevented the growth of the tumor in 56% of the treated eyes. In 98% of the control eyes, malignant melanoma grew rapidly and extensively.

(Arch Ophthalmol 95:2214-2217, 1977)

References
1.
Guerin C:  The history of BCG , in Rosenthal SR (ed): BCG Vaccination Against Tuberculosis . Boston, Little, Brown and Co, 1957, pp 48-53.
2.
Bast RC, Zbar B, Borsos T, et al:  BCG and cancer: Part I . N Engl J Med 290:1413-1420, 1974.Article
3.
Bast RC, Zbar B, Borsos T, et al:  BCG and cancer: Part II . N Engl J Med 290:1458-1469, 1974.Article
4.
Humphrey LJ, Murray DR, Boehm OR:  Effect of tumor vaccines in immunizing patients with cancer . Surg Gynecol Obstet 132:437-442, 1971.
5.
Bluming AZ, Vogel CL, Ziegler JL, et al:  Immunological effects of BCG in malignant melanoma: Two modes of administration compared . Ann Intern Med 76:405-411, 1972.Article
6.
Nathanson L:  Regression of intradermal malignant melanoma after intralesional injection of Mycobacterium bovis strain BCG . Cancer Chemother Rep 56:659-665, 1972.
7.
Gutterman J, Mavligit G, McBride C, et al:  BCG stimulation of immune responsiveness in patients with malignant melanoma . Cancer 32:321-327, 1973.Article
8.
Ikonopisov RL:  The rationale of immunostimulation procedures in the therapeutic approach to malignant melanoma of the skin . Tumori 58:121-128, 1972.
9.
Seigler MF, Shingleton WW, Metzgar RS, et al:  Nonspecific and specific immunotherapy in patients with melanoma . Surgery 72:162-179, 1972.
10.
Eilber FR, Morton DL, Holmes EC, et al:  Adjuvant immunotherapy with BCG in treatment of regional lymph node metastases from malignant melanoma . N Engl J Med 294:237-240, 1976.Article
11.
Zbar B, Tanaka T:  Immunotherapy of cancer: Regression of tumors after intralesional injection of living Mycobacterium bovis . Science 172:271-273, 1971.Article
12.
Fortner JG, Allen AC:  Hitherto unreported malignant melanomas in the Syrian hamster: An experimental counterpart of the human malignant melanomas . Cancer Res 18:98-104, 1958.
13.
Morton DL, Eilber FR, Malmgren RA, et al:  Immunological factors which influence response to immunotherapy in malignant melanoma . Surgery 68:158-164, 1970.
14.
Manna MG Jr, Snodgrass MJ, Zbar B, et al:  Histopathology of Mycobacterium bovis (BCG)-mediated tumor regression . Natl Cancer Inst Monogr 35:245-257, 1972.
15.
Zbar B:  Tumor regression mediated by Mycobacterium bovis (strain BCG) . Natl Cancer Inst Monogr 35:341-344, 1972.
16.
Keller R:  Cytostatic elimination of syngeneic rat tumor cells in vitro by nonspecifically activated macrophages . J Exp Med 138:625-644, 1973.Article
17.
Alexander P:  Activated macrophages in the anti-tumor action of BCG . Natl Cancer Inst Monogr 39:127-133, 1973.
18.
Holterman UA, Casale GP, Klein E:  Tumor cell destruction by macrophages .J Med 3:305-309, 1972.Article
19.
Pincus WB:  Tissue injury and delayed-type hypersensitivity . Ann Allergy 28:93-97, 1970.
×